MIM
ADCT icon

Monashee Investment Management’s ADC Therapeutics ADCT Stock Holding History

Monashee Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500,000
Closed -$2.25M – 77
2024
Q1 		$2.25M Buy
+500,000
New +$1.84M 0.27% 58
2020
Q4 		– Sell
-100,000
Closed -$3.3M – 282
2020
Q3 		$3.3M Buy
+100,000
New +$4.33M 0.71% 30

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Monashee Investment Management's ADCT Position: Q2 2024 in Review

Monashee Investment Management sold out of ADC Therapeutics (ADCT) in Q2 2024, closing a stake of 500,000 shares — an estimated $2.25M sold.

Monashee Investment Management first reported a position in ADCT in Q3 2020 and held it in 2 quarters. The position peaked at $3.3M in Q3 2020. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

  • Monashee Investment Management reported no remaining ADC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 500,000 ADC Therapeutics shares in Q2 2024, an estimated $2.25M.
  • Monashee Investment Management first reported a position in ADC Therapeutics in Q3 2020 and held it in 2 quarters.
  • Monashee Investment Management's ADC Therapeutics position peaked at $3.3M in Q3 2020.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.